Phaxiam Therapeutics
PHXM
PHXM was delisted on the 8th of March, 2024.
7 hedge funds and large institutions have $51.6M invested in Phaxiam Therapeutics in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
8% more capital inflows, than outflows
Capital inflows: $2.89M | Capital outflows: $2.67M
0.08% more ownership
Funds ownership: 14.75% → 14.83% (+0.08%)
13% less funds holding
Funds holding: 8 → 7 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.52M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$77K |
| 3 |
Millennium Management
New York
|
-$59.8K |
| 4 |
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$12K |
PHXM Hedge Fund Activity: Q2 2018 in Review
7 of the 4,387 institutional investors tracked by Wall St. Rank reported a position in Phaxiam Therapeutics (PHXM) for Q2 2018, worth a combined $51.6M — down 46% from $96M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHXM and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.89M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.52M sold.
- 7 institutional investors held Phaxiam Therapeutics (PHXM) as of Q2 2018, down from 8 in Q1 2018.
- Funds reported $51.6M of Phaxiam Therapeutics stock for Q2 2018, down 46% quarter-over-quarter.
- 1 fund opened new Phaxiam Therapeutics positions in Q2 2018 and 2 closed out, a net change of -1 holder.
- The largest Phaxiam Therapeutics buyer in Q2 2018 was EcoR1 Capital, an estimated $2.89M added.
- The largest Phaxiam Therapeutics seller in Q2 2018 was Sphera Funds Management, an estimated $2.52M sold.
Based on aggregated 13F filings for Q2 2018.